Can ELV sustain its growth into 2025?

**Elevance Health (ELV) is well-positioned to sustain its growth into 2025**, considering the following factors:

1. **Stable Financial Performance**: ELV's financials show resilience with a consistent revenue growth of 2.9% to $175.2 billion for the year 2024, despite a slight decline in adjusted EPS. The company's ability to grow revenue and manage expenses indicates a strong foundation for sustained growth.
2. **Dividend and Shareholder Returns**: ELV has a history of consistent dividend payments, with a recent increase of 4.9%. The company's dividend yield of 1.59% exceeds the industry average, reflecting a commitment to returning value to shareholders.
3. **Strategic Initiatives**: ELV has optimized its government segment and strengthened its commercial business, leading to steady membership growth. The company's strategic resource reallocation and prudent acquisitions suggest a forward-looking approach to growth.
4. **Market Position and Outlook**: ELV's leading position in the health benefits market, serving nearly 46 million members, provides a solid base for growth. Analysts have raised price targets, indicating optimism about ELV's EPS growth outlook.
5. **Industry Trends and Growth Prospects**: The healthcare insurance market is projected to grow significantly, with a compound annual growth rate (CAGR) of 9.7% from 2025 to 2032. This macroeconomic trend is likely to support ELV's growth trajectory.

In conclusion, ELV's stable financial performance, strategic initiatives, market position, and favorable industry trends suggest that the company is well-equipped to sustain its growth into 2025.